Anupam Rasayan India Ltd has pledged 1,03,61,785 equity shares, representing 9.10% of its total share capital, in favour of Catalyst Trusteeship Limited. The pledge was executed in two tranches during late September 2026.

The disclosure was filed under Regulation 29(1) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Catalyst Trusteeship Limited is acting as the Debenture Trustee on behalf of debenture holders, securing the company's debt obligations through this encumbrance.

Pledge Details and Timeline

The acquisition of rights over these shares occurred via two distinct dates in September 2026. The total number of shares pledged amounts to 1,03,61,785, with no prior holding recorded by the acquirer or persons acting in concert before this transaction.

Capital Structure Impact

The pledge does not alter the total share capital or voting rights structure of the company. The equity share capital remains unchanged at ₹1,13,84,98,410, comprising 11,38,49,841 shares with a face value of ₹10 each.

What the Numbers Show

The creation of a pledge on 9.10% of the total equity indicates a significant collateralisation effort tied to debt instruments. Since Catalyst Trusteeship Limited is acting specifically as a Debenture Trustee, this move directly secures the interests of bondholders rather than representing a change in promoter ownership or a strategic stake sale. The split execution across two dates suggests a phased finalisation of the security agreement.

Anupam Rasayan India Ltd has completed the acquisition of a 50.07% controlling stake in Bliss GVS Pharma Limited, officially assuming promoter status as of September 28, 2026. The final step involved an on-market purchase of 22.5 lakh equity shares at ₹723.29 per share, pushing the aggregate holding above the 50% threshold required for control.

This transaction marks the company's third strategic inorganic move, expanding its presence into finished dosage formulations and creating an integrated platform with pro-forma revenue exceeding ₹4,000 crore. The acquisition was executed through Mates Visa Consultancy Private Limited (MVCPL), a wholly owned subsidiary. The deal follows a definitive agreement signed on May 23, 2026, and the completion of mandatory open offer processes.

Financing structure and security details

The financing architecture relies on debt instruments issued by MVCPL, secured by Anupam Rasayan. Earlier disclosures confirmed the execution of security documents for the ₹300 crore senior secured unrated unlisted redeemable non-convertible debentures (NCDs). These NCDs, issued in September 2026, have a maximum tenor of 48 months.

To secure these instruments, Anupam Rasayan created first-ranking exclusive charges:

• Pledge of MVCPL Shares: A deed of pledge covers 100% of MVCPL equity shares held by the parent company.
• Pledge of Purebliss Stake: A separate pledge covers the company’s 15% stake in Purebliss Pharma Solutions Private Limited.
• Corporate Guarantee: An unconditional corporate guarantee supports all amounts payable under the MVCPL Debenture Trust Deed.

A call option agreement grants Purebliss the right to purchase MVCPL securities from Anupam Rasayan at ₹1.00 upon specific trigger events, such as defaults.

Strategic integration and portfolio expansion

Bliss GVS Pharma, founded in 1984, operates six manufacturing facilities in Maharashtra certified to US FDA, EU-GMP, and WHO-GMP standards. It holds over 150 brands across therapeutic segments including anti-malarial, anti-fungal, and cardiovascular therapies. With manufacturing capacity utilisation at approximately 30%, the business offers significant headroom for growth.

This acquisition represents forward integration, complementing previous moves: backward integration via Tanfac Industries (specialty fluorides) and global manufacturing expansion through Jayhawk Fine Chemicals (US-based). Together, these transactions aim to build a diversified platform spanning key starting materials, intermediates, specialty chemicals, and finished formulations.

What the numbers show

The combined entity’s pro-forma revenue is projected at over ₹4,000 crore, comprising ₹1,676 crore from Anupam Rasayan standalone, ₹711 crore from Tanfac Industries, ₹722 crore from Jayhawk Fine Chemicals, and ₹927 crore from Bliss GVS Pharma. The projected EBITDA stands at approximately ₹834 crore.

The final on-market transaction valued Bliss GVS shares at ₹723.29, significantly higher than the initial open offer price of ₹299 per share. This price differential reflects the market's reassessment of Bliss GVS following the announcement of control, highlighting the premium paid for the remaining equity to secure full consolidation. The acquisition price values Bliss GVS at approximately 24x LTM earnings for the initial tranche, a multiple lower than that of the parent company, suggesting potential earnings accretion for shareholders.